---
title: "Intratympanic Steroids for Preventing Cisplatin Ototoxicity: Systematic Review Findings"
id: "pubmed-43052063"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-43052063"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/43052063/"
doi: "10.1159/aud/abnag002"
published_at: "2026-11-19T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Intratympanic Steroids for Preventing Cisplatin Ototoxicity: Systematic Review Findings
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-43052063
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/43052063/)
- **DOI:** [10.1159/aud/abnag002](https://doi.org/10.1159%2Faud%2Fabnag002)
- **Published At:** 2026-11-19T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- A systematic review examined randomized controlled trials (RCTs) testing **intratympanic steroids** to prevent **cisplatin-induced hearing loss**. - Investigators searched PubMed, Cochrane Library, and Scopus for studies published January 2004–July 2023, using predefined PICOS criteria and PRISMA methodology. - The search returned 383 records; title/abstract screening reduced this to 42 full-text reports and, after eligibility assessment, four RCTs were included for qualitative synthesis. - Risk-of-bias assessment identified high risk for allocation concealment across all four trials and substantial risk of detection bias in three trials, according to the authors. - Evidence quality (GRADE) varied: one RCT rated high, two rated moderate, and one rated low quality. - The pooled body of RCTs did not demonstrate a consistent otoprotective benefit from intratympanic steroid administration; no study provided uniformly high-quality evidence for a significant protective effect. - The review authors attributed inconsistent outcomes to methodological heterogeneity: variable steroid dose/concentration, timing relative to cisplatin, and differing patient populations. - The authors concluded that current RCT evidence is insufficient to establish intratympanic steroid therapy as a standard otoprotective intervention and recommended rigorously designed, standardized RCTs to resolve remaining uncertainties.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/43052063/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43052063%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/43052063/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/43052063/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/43052063/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/43052063/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/43052063/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/43052063/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43052063%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43052063%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/43052063/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43052063/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43052063/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/43052063/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43052063/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/43052063/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/43052063/#abstract) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/43052063/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/43052063/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/43052063/#substances) Title & authors Abstract Publication types MeSH terms Substances Audiol Neurootol Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Audiol+Neurootol%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Audiol+Neurootol%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43052063/) . 2026 Nov 19;31(5):392-400. doi: 10.1159/aud/abnag002. # Intratympanic Steroid Regimen for Prevention of Cisplatin-Induced Hearing Loss: A Systematic Review [Musaed Alzahrani](https://pubmed.ncbi.nlm.nih.gov/?term=Alzahrani+M&cauthor_id=43052063)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43052063/#full-view-affiliation-1 "Department of Otolaryngology, King Fahad Specialist Hospital, Dammam, Saudi Arabia."), [Zohour A Almalki](https://pubmed.ncbi.nlm.nih.gov/?term=Almalki+ZA&cauthor_id=43052063)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43052063/#full-view-affiliation-2 "Department of Otolaryngology, Head and Neck Surgery, Makkah Health Cluster, Makkah, Saudi Arabia."), [Shatha Alqahtani](https://pubmed.ncbi.nlm.nih.gov/?term=Alqahtani+S&cauthor_id=43052063)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/43052063/#full-view-affiliation-3 "Department of Otolaryngology, Alhada Armed Forces Hospital, Taif, Saudi Arabia."), [Farah S Alnemari](https://pubmed.ncbi.nlm.nih.gov/?term=Alnemari+FS&cauthor_id=43052063)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/43052063/#full-view-affiliation-4 "Department of Otolaryngology, Head and Neck Surgery, Taif Health Cluster, Taif, Saudi Arabia."), [Fahad S Alghamdi](https://pubmed.ncbi.nlm.nih.gov/?term=Alghamdi+FS&cauthor_id=43052063)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43052063/#full-view-affiliation-2 "Department of Otolaryngology, Head and Neck Surgery, Makkah Health Cluster, Makkah, Saudi Arabia."), [Sarah O Aljuaid](https://pubmed.ncbi.nlm.nih.gov/?term=Aljuaid+SO&cauthor_id=43052063)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/43052063/#full-view-affiliation-5 "Department of General Surgery, Taif Health Cluster, Taif, Saudi Arabia.") Affiliations Expand ### Affiliations * 1 Department of Otolaryngology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. * 2 Department of Otolaryngology, Head and Neck Surgery, Makkah Health Cluster, Makkah, Saudi Arabia. * 3 Department of Otolaryngology, Alhada Armed Forces Hospital, Taif, Saudi Arabia. * 4 Department of Otolaryngology, Head and Neck Surgery, Taif Health Cluster, Taif, Saudi Arabia. * 5 Department of General Surgery, Taif Health Cluster, Taif, Saudi Arabia. * PMID: **43052063** * DOI: [ 10.1159/aud/abnag002 ](https://doi.org/10.1159/aud/abnag002) Item in Clipboard # Intratympanic Steroid Regimen for Prevention of Cisplatin-Induced Hearing Loss: A Systematic Review Musaed Alzahrani et al. Audiol Neurootol. 2026. Show details Display options Display options Format Abstract PubMed PMID Audiol Neurootol Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Audiol+Neurootol%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Audiol+Neurootol%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43052063/) . 2026 Nov 19;31(5):392-400. doi: 10.1159/aud/abnag002. ### Authors [Musaed Alzahrani](https://pubmed.ncbi.nlm.nih.gov/?term=Alzahrani+M&cauthor_id=43052063)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43052063/#short-view-affiliation-1 "Department of Otolaryngology, King Fahad Specialist Hospital, Dammam, Saudi Arabia."), [Zohour A Almalki](https://pubmed.ncbi.nlm.nih.gov/?term=Almalki+ZA&cauthor_id=43052063)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43052063/#short-view-affiliation-2 "Department of Otolaryngology, Head and Neck Surgery, Makkah Health Cluster, Makkah, Saudi Arabia."), [Shatha Alqahtani](https://pubmed.ncbi.nlm.nih.gov/?term=Alqahtani+S&cauthor_id=43052063)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/43052063/#short-view-affiliation-3 "Department of Otolaryngology, Alhada Armed Forces Hospital, Taif, Saudi Arabia."), [Farah S Alnemari](https://pubmed.ncbi.nlm.nih.gov/?term=Alnemari+FS&cauthor_id=43052063)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/43052063/#short-view-affiliation-4 "Department of Otolaryngology, Head and Neck Surgery, Taif Health Cluster, Taif, Saudi Arabia."), [Fahad S Alghamdi](https://pubmed.ncbi.nlm.nih.gov/?term=Alghamdi+FS&cauthor_id=43052063)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43052063/#short-view-affiliation-2 "Department of Otolaryngology, Head and Neck Surgery, Makkah Health Cluster, Makkah, Saudi Arabia."), [Sarah O Aljuaid](https://pubmed.ncbi.nlm.nih.gov/?term=Aljuaid+SO&cauthor_id=43052063)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/43052063/#short-view-affiliation-5 "Department of General Surgery, Taif Health Cluster, Taif, Saudi Arabia.") ### Affiliations * 1 Department of Otolaryngology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. * 2 Department of Otolaryngology, Head and Neck Surgery, Makkah Health Cluster, Makkah, Saudi Arabia. * 3 Department of Otolaryngology, Alhada Armed Forces Hospital, Taif, Saudi Arabia. * 4 Department of Otolaryngology, Head and Neck Surgery, Taif Health Cluster, Taif, Saudi Arabia. * 5 Department of General Surgery, Taif Health Cluster, Taif, Saudi Arabia. * PMID: **43052063** * DOI: [ 10.1159/aud/abnag002 ](https://doi.org/10.1159/aud/abnag002) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract **Introduction:** Cisplatin exhibits a steep dose-response relationship, wherein its therapeutic efficacy increases significantly with higher doses. This dose escalation, however, is limited by severe adverse effects, notably ototoxicity, which can lead to permanent and disabling hearing loss. The objective of this review was to evaluate the potential efficacy of intratympanic steroid administration (ITD) in preventing cisplatin-induced hearing loss (CiHL). **Methods:** A systematic literature search was conducted using PubMed, Cochrane Library, and Scopus databases for evidence-based research articles published between January 2004 and July 2023. The search strategy focused on intratympanic steroids for cisplatin-related ototoxicity. Two independent reviewers performed the search, screening, and study selection according to predefined Population, Intervention, Comparison, Outcome, Study design (PICOS) criteria. Only randomized controlled trials (RCTs) involving patients receiving cisplatin and treated with an intratympanic steroid regimen were included. The review process adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. **Results:** The initial database and manual searches identified 383 records. Following title and abstract screening, 42 articles underwent full-text review. After applying the eligibility criteria, 38 studies were excluded, resulting in four RCTs for qualitative synthesis. Risk of bias (RoB) assessment revealed a high-risk concerning allocation concealment in all four studies. Additionally, a substantial risk of detection bias was present in three RCTs. According to the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) framework, the overall quality of evidence was rated as high in one study, moderate in two, and low in one. **Conclusion:** This review did not confirm a consistent otoprotective benefit of intratympanic steroid administration against CiHL. None of the included studies demonstrated high-quality evidence for a significant protective effect. The available RCTs report inconsistent outcomes and collectively fail to establish a definitive therapeutic advantage for ITD in this context. These discrepancies may be attributable to methodological variations across studies, including differences in steroid dosage, concentration, timing of administration relative to cisplatin therapy, and patient populations. Further rigorously designed RCTs with standardized protocols are warranted to definitively assess the potential role of ITD in mitigating cisplatin ototoxicity. **Keywords:** Cisplatin; Hearing loss; Intratympanic steroids; Otoprotection; Ototoxicity; Systematic review. © The Author(s) 2026. Published by S. Karger AG. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Publication types * Systematic Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Systematic+Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Systematic+Review) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43052063/) ## MeSH terms * Antineoplastic Agents* / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2Fadverse+effects%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43052063/) * Cisplatin* / adverse effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cisplatin%2Fadverse+effects%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cisplatin) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43052063/) * Glucocorticoids* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Glucocorticoids%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Glucocorticoids) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43052063/) * Hearing Loss* / chemically induced Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Hearing+Loss%2Fchemically+induced%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Hearing+Loss) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43052063/) * Hearing Loss* / prevention & control Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Hearing+Loss%2Fprevention+and+control%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Hearing+Loss) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43052063/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43052063/) * Injection, Intratympanic Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Injection%2C+Intratympanic%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Injection%2C+Intratympanic) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43052063/) * Ototoxicity* / prevention & control Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Ototoxicity%2Fprevention+and+control%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Ototoxicity) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43052063/) * Steroids* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Steroids%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Steroids) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43052063/) ## Substances * Cisplatin Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cisplatin%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Cisplatin%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43052063/) * Antineoplastic Agents Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Antineoplastic+Agents%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43052063/) * Steroids Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Steroids%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Steroids%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43052063/) * Glucocorticoids Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Glucocorticoids%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Glucocorticoids%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43052063/) [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM **Send To** * [Clipboard](https://pubmed.ncbi.nlm.nih.gov/43052063/) * [Email](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43052063%2F%23open-email-panel) * [Save](https://pubmed.ncbi.nlm.nih.gov/43052063/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43052063%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43052063%2F%23open-collections-panel) * [Citation Manager](https://pubmed.ncbi.nlm.nih.gov/43052063/) [x] NCBI Literature Resources [MeSH](https://www.ncbi.nlm.nih.gov/mesh/) [PMC](https://www.ncbi.nlm.nih.gov/pmc/) [Bookshelf](https://www.ncbi.nlm.nih.gov/books) [Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited. Follow NCBI [ Twitter ](https://twitter.com/ncbi) [ Facebook ](https://www.facebook.com/ncbi.nlm) [ LinkedIn ](https://www.linkedin.com/company/ncbinlm) [ GitHub ](https://github.com/ncbi) [ ](https://ncbiinsights.ncbi.nlm.nih.gov/) [Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html) * [ Twitter ](https://twitter.com/NLM_NIH) * [ SM-Facebook ](https://www.facebook.com/nationallibraryofmedicine) * [ SM-Youtube ](https://www.youtube.com/user/NLMNIH) National Library of Medicine [8600 Rockv
## Related Clinical Research

- [TX5 photosensitizer targets mitochondrial DNA G-quadruplexes to bypass cisplatin resistance in lun](https://medichelpline.com/clinical-feed/pubmed-42933202.md) (DOI: 10.1016/j.bioorg.2026.110694)
- [Advanced glycation end products drive ferroptotic injury via the miR-362-3p/SLC7A11/GPX4 axis in r](https://medichelpline.com/clinical-feed/pubmed-42767451.md) (DOI: 10.1016/j.lfs.2026.124705)
- [Correction: Image replacement and data notes for niosomal cisplatin–vorinostat formulation](https://medichelpline.com/clinical-feed/plos-one-19-correction-development-of-niosomal-nanoparticles-loaded-with-cisplatin-and.md)
- [Pollen size shifts after whole genome duplication in autotetraploids](https://medichelpline.com/clinical-feed/biorxiv-17-biased-evolution-of-pollen-size-after-whole-genome-duplication.md)
- [Nelfinavir enhances cisplatin-induced immunogenic cell death in ovarian cancer cells](https://medichelpline.com/clinical-feed/biorxiv-6-combined-nelfinavir-and-cisplatin-treatment-promotes-inflammatory-signaling-and.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.